Kenvue delivered first-quarter financial results that outpaced Wall Street projections, with its skincare and beauty brands contributing notably to top-line momentum. The company reported adjusted earnings per share of $0.32, above the market consensus of $0.26, while quarterly net sales reached $3.91 billion, a 4.5% increase from the prior year and ahead of analysts' estimates of $3.84 billion.
Sales at Kenvue's skin health and beauty division, which includes well-known product lines in its portfolio, rose 8.4% to $1.06 billion for the three months ended March 29, lifted by broad-based increases across global markets.
Management reiterated confidence in its strategic direction as the company advances both an internal transformation and the pending transaction with Kimberly-Clark. "We remain confident ... as we accelerate our organization and business transformation through our new strategic plans and work toward completing our value-creating combination with Kimberly-Clark in the second half of this year," said CEO Kirk Perry.
The takeover by Kimberly-Clark, a transaction valued at about $40 billion, remains on track to close in the second half of the year, according to Kenvue's commentary alongside the quarterly results.
Kenvue also disclosed an anticipated curtailment of operations tied to a restructuring plan. The company expects pre-tax restructuring expenses and other charges to total approximately $250 million in the current year as it implements those changes.
Market analysts noted that while the company's public tenure has faced challenges, the latest financial picture suggests stabilization. "Kenvue's time as a public company has been tumultuous … Fundamentals still matter but in the near term will take a backseat to the deal and ongoing litigation headlines which we believe will take time to resolve," said RBC Capital Markets analyst Nik Modi, who described the reported results as bullish for Kimberly-Clark and observed signs that "Kenvue's fundamentals seem to be stabilizing."
Investors will likely watch the timetable for closing the acquisition and the progress of restructuring-related activities closely, as both have direct implications for near-term financial results and the combined company's strategic positioning once the deal is completed.
Quarterly highlights
- Adjusted EPS: $0.32 versus $0.26 expected (LSEG data).
- Net sales: $3.91 billion, up 4.5% year-over-year, above $3.84 billion consensus.
- Skin health and beauty net sales: $1.06 billion, up 8.4% for the quarter ended March 29.
- Expected pre-tax restructuring charges and other expenses: about $250 million for the year.
- Pending acquisition: Kimberly-Clark buyout valued at about $40 billion, expected to close in the second half of the year.